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CHEMOKINES, CYTOKINES, AND INTERLEUKINS
Chemokine and chemokine receptor expression during colony stimulating
factor-1–induced osteoclast differentiation in the toothless osteopetrotic rat: a key
role for CCL9 (MIP-1) in osteoclastogenesis in vivo and in vitro
Meiheng Yang, Genevie`ve Mailhot, Carole A. MacKay, April Mason-Savas, Justin Aubin, and Paul R. Odgren
Osteoclasts differentiate from hematopoi-
etic precursors under systemic and local
controls. Chemokines and receptors di-
rect leukocyte traffic throughout the body
and may help regulate site-specific bone
resorption. We investigated bone gene
expression in vivo during rapid oste-
oclast differentiation induced by colony-
stimulating factor 1 (CSF-1) in Csf1-null
toothless (tl/tl) rats. Long-bone RNA from
CSF-1–treated tl/tl rats was analyzed by
high-density microarray over a time
course. TRAP (tartrate-resistant acid
phosphatase)–positive osteoclasts ap-
peared on day 2, peaked on day 4, and
decreased slightly on day 6, as marrow
space was expanding. TRAP and cathep-
sin K mRNA paralleled the cell counts. We
examined all chemokine and receptor
mRNAs on the arrays. CCL9 was strongly
induced and peaked on day 2, as did its
receptor, CCR1, and regulatory receptors
c-Fms (CSF-1 receptor) and RANK (recep-
tor activator of nuclear factor B). Other
chemokines and receptors showed little
or no significant changes. In situ hybrid-
ization and immunohistochemistry re-
vealed CCL9 in small, immature oste-
oclasts on day 2 and in mature cells at
later times. Anti-CCL9 antibody inhibited
osteoclast differentiation in culture and
significantly suppressed the osteoclast
response in CSF-1–treated tl/tl rats. While
various chemokines have been impli-
cated in osteoclastogenesis in vitro, this
first systematic analysis of chemokines
and receptors during osteoclast differen-
tiation in vivo highlights the key role of
CCL9 in this process. (Blood. 2006;107:
2262-2270)
© 2006 by The American Society of Hematology
Introduction
Osteoclasts are specialized, multinucleated bone-resorbing cells
that differentiate by fusion of mononuclear hematopoietic precur-
sor cells of the myeloid lineage. This complex process is closely
regulated and requires numerous systemic and local factors,
including growth factors, hormones, transcription factors, en-
zymes, and transporters for resorption to occur at the necessary
levels and appropriate skeletal sites. The anabolic and catabolic
activities of osteoblasts, osteocytes, and osteoclasts are normally
exquisitely balanced to maintain normal bone mass.1 Excessive
resorptive activity causes bone deficiency, for example in osteopo-
rosis, arthritis, or other bone-loss syndromes, whereas defective
resorptive activity can cause osteopetrosis, characterized by dense,
brittle bones, lack of marrow cavities, and lack of teeth due to
blockage of eruption.2
There are many known mutations in human patients and in
animal models that inhibit osteoclastogenesis and/or osteoclast
activity.3,4 Each of these osteopetrotic mutations has provided
insights into mechanisms that regulate the differentiation and
activity of osteoclasts. Two growth factors essential for early steps
in the commitment of F4/80-positive, mononuclear leukocytes to
differentiate along the osteoclast pathway are colony stimulating
factor-1 (CSF-1, or M-CSF) and the tumor necrosis factor (TNF)
family member, RANKL (also called TRANCE, OPGL, or TN-
FSF11), which are supplied in the skeleton by osteoblasts. Follow-
ing CSF-1 and RANKL binding, precursor cells fuse and become
multinucleated, attach to bone, differentiate, and become active,
bone-resorbing cells. One naturally occurring osteopetrotic model
is the toothless (tl/tl) rat,5,6 an autosomal recessive mutation in
which a frameshift in the CSF-1 gene causes severe osteopetrosis
due a virtually complete lack of osteoclasts.7,8 Injections of soluble,
recombinant CSF-1 rapidly restore osteoclast populations and
rescue many, but not all, aspects of the phenotype.9-11
While cell and organ culture models are essential experimental
tools, no ex vivo system can replicate the complex interactions that
occur in living bone. The CSF-1-treated tlCsf1/tlCsf rat thus provides
a powerful model to study molecular and cellular events that
accompany osteoclastogenesis in vivo. We used high-density
microarrays to investigate gene expression changes that occur in
the tibia during the burst of osteoclastogenesis caused by CSF-1
injections in the tl/tl rat. One gene that was very highly up-
regulated was the chemokine CCL9 (also called MIP-1, CCF18,
Scya9, or MRP-2).12 Recent cell culture studies by several
groups13-17 suggest that chemokines and their receptors could play
roles in extravasation, migration, and/or survival of osteoclastic
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cells in vivo. In addition, CCL3 (MIP-1) has been implicated in
local osteolysis due to myeloma18 and prosthesis wear particles.19
Chemokines are a large family of small, secreted (with very few
exceptions) proteins that regulate the migration and interactions
of white blood cells of all types.20-22 Their receptors are also
numerous: some can bind more than one chemokine, and vice
versa. This produces some redundancies and overlap of functions.
Chemokines are categorized structurally based on the arrangement
of N-terminal region Cys residues. CC denotes adjacent cysteines
and CX(N)C denotes a residue (or the number of residues) between
them. They are also characterized as “homeostatic” or “inflamma-
tory,” depending on whether they participate in the normal
regulation of leukocyte differentiation and targeting or are mainly
involved in inflammatory responses. Some are known as “dual-
function” chemokines, participating in both processes.20 The
chemokine receptors are named by the structural category of their
ligands, followed by a number. For example, CCR1 is the first
member of the family of receptors that bind ligands of the CC
subfamily. When ligand binds, receptors activate cellular responses
via coupled G-proteins, inducing chemotactic and other
cellular responses.
Recent investigations have surveyed chemokine and receptor
expression in vitro in a culture model in which mouse bone marrow
cells were induced to differentiate under the influence of CSF-1 and
RANKL.14 CCL9 mRNA expression increased markedly in this
system, suggesting a role in osteoclast differentiation. During the
course of our investigations, another study of CCL9 in differentiat-
ing mouse osteoclast cultures showed similar in vitro up-regulation
of CCL9, that CCL9 promoted survival of mouse osteoclast-
lineage cells, and that anti-CCL9 antibody could inhibit mouse
osteoclast differentiation in cultures.13 How these model systems
correspond to the complexities of in vivo osteoclastogenesis has
not been established. Here we report our findings of strong
up-regulation of CCL9 and its receptor, CCR1, during rapid
osteoclast differentiation in CSF-1–treated tl/tl rats and that
anti-CCL9 antibody inhibited osteoclast differentiation not only in
cultures, but also in vivo, demonstrating a genuine physiologic role
for CCL9 in osteoclastogenesis.
The evolutionary conservation of the chemokines and their
receptors is looser than many other gene families. Given their
biological importance, the complexity of their ligand/receptor cross
reactivities, and the dependence of many lines of investigation on
animal models, we also present results of comparative sequence
analysis of chemokines and their receptors in rat versus mouse and
discuss comparisons with the human system.
Materials and methods
Animals and tissue samples
Procedures involving animals were carried out under University of
Massachusetts Medical School Institution of Animal Care and Use Commit-
tees–approved protocols. Three-week-old tlCSF1/tlCSF1 rats and / litter-
mates were obtained from the inbred colony maintained under specific
pathogen–free (SPF) conditions at the University of Massachusetts Medical
School. Mutants and wild-type littermates were identified by neonatal
X-ray and by polymerase chain reaction (PCR) genotyping.8 Beginning at
21 days after birth, some tl/tl animals and wild-type (/) littermates
received daily injections of 106 U of recombinant human CSF-1 (gener-
ously provided by Chiron, Emeryville, CA) as described,9,11 a dose that
produces roughly normal circulating levels of CSF-1. Preliminary experi-
ments established the timing of the osteoclast response. At appropriate time
points, tibiae and femora were harvested. For RNA extraction, bones were
carefully dissected to remove extraneous connective tissue and muscle, and
joint cartilage and epiphyseal growth plates were also removed, leaving the
metaphysis and diaphysis. Bones were split longitudinally and flushed with
cold phosphate-buffered saline (PBS) to remove as much marrow as
possible, although in untreated and 2-day-treated mutants, no discernible
marrow spaces had formed. Dissected bones were flash-frozen in liquid
nitrogen for later RNA extraction. For studies of in vivo inhibition of
osteoclast differentiation by anti-CCL9, tl/tl rats were injected at 20 days
after birth with 50 g affinity-purified rabbit anti-murine CCL9 (MIP-1)
antibody (Peprotech, Rocky Hill, NJ) in 100 L PBS, and again on days 21
and 23, with 50 g anti-CCL9 plus 106 U CSF-1 in 100 L PBS. On
alternate days, they received only CSF-1, as described.
Osteoclast counts
Contralateral tibiae were dissected from animals used in the CSF-1 time
course, immersion-fixed in glutaraldehyde and paraformaldehyde, deminer-
alized in EDTA, embedded in glycol methacrylate, and processed for TRAP
(tartrate-resistant acid phosphatase) histochemistry to visualize osteoclasts
as described previously.23,24 TRAP-positive cells were counted as follows.
A histologic microscope with an attached digitizing tablet was used to
project a fixed rectangle into the field of view. With a  20 objective, the
size of the rectangle seen in the field of view was 755  545 m, and all the
TRAP-positive cells in the rectangle were counted. The rectangle was
positioned in the metaphysis just below the chondro-osseous junction of the
proximal tibia or the distal femur for Area A, and it was moved toward the
diaphysis by 1.5 times its height for counting Area B. Counts were done by
2 individuals on each section, at least 6 sections were counted per animal,
and at least 3 individual animals were evaluated for each time point and
condition. Alternate sections were briefly counterstained with toluidine blue
(0.1%) to visualize the tissue context of the osteoclasts.
RNA extraction and microarray analysis
Each time point was measured in each of 4 animals using RNA from
cleaned limb bones (1 tibia and 1 femur). Frozen bones were pulverized in a
Bessler mortar and pestle cooled with dry ice, and RNA was extracted from
the bone powder using Trizol (Invitrogen, Carlsbad, CA). After extraction,
RNA was processed for microarray analysis according to Affymetrix’s
instructions (Santa Clara, CA). Briefly, RNA was cleaned using RNeasy
columns (Qiagen, Valencia, CA), reverse transcribed (Superscript; Invitro-
gen), and transcribed in vitro to make cRNA with biotin incorporated
(ENZO RNA in vitro transcript kit; Enzo Biochem, Farmingdale, NY). The
cRNA was then subjected to limited alkaline hydrolysis for hybridization
with the DNA microarrays. High-density microarray analysis was done
using the rat RAE230 rat chipset (Affymetrix) according to manufacturer’s
instructions. This set represents some 30 200 different cDNA sequences on
2 chips. For each chip set, we tested RNA from a single animal. Chip image
files were obtained through Affymetrix GeneChip software (MAS5).
Subsequently, D-Chip (http://www.biostat.harvard.edu/complab/dchip/) anal-
ysis was performed to analyze differentially expressed genes, and further
analyses were done using Excel (Microsoft, Redmond, WA). Expression
levels are means for 4 individual animals, given in relative units,
normalized to GAPDH mRNA.
Real-time PCR
RNA was isolated and reverse-transcribed, and real-time reverse transcrip-
tase (RT)–PCR was carried out as described.12 Briefly, the LightCycler
System (Roche Diagnostics, Indianapolis, IN) was used according to the
manufacturer’s instructions. Reactions were set up in micro capillary tubes
using 0.5 L cDNA with 9.5 L of a LightCycler FastStart DNA Master
SYBR Green I mix (Roche Diagnostics) to which gene-specific upstream
and downstream PCR primers had been added. The final concentrations of
the reaction components were 1.0 mM of each primer and 2.5 mM MgCl2.
The primers for CCL9 were 5-GATGAAGCCCTTTCATACTGC -3
(forward) and 5-GTGGTTGTGAGTTTTGCTCCAATC -3 (reverse). Prim-
ers for RANK were 5-CTGCTCCTCTTCATCTCTGTG -3 (forward) and
5-CTTCTGGAACCATCTTCTCCTC-3 (reverse). The cycling conditions
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were 95°C preincubation for 10 minutes; 95°C for 10 seconds; 55°C for 10
seconds; and 72°C for 5 seconds; for 45 cycles. A dilution series of a test
sample was set up for the standard curve. Parallel running of GAPDH was
used for normalization, and results are given in relative units.
Osteoclast differentiation in vitro
Osteoclasts were differentiated in culture according to standard proce-
dures.25 Bone marrow was harvested from tibiae and femora of 2-week-old
wild-type rats by flushing with cold PBS, and the resulting cell suspension
was centrifuged on Histopaque-1077 (Sigma, St Louis, MO) to isolate the
mononuclear cell fraction. After washing in PBS, the cells were suspended
in complete –modified Eagle medium (MEM) with 10% fetal bovine
serum, plated in 75-cm2 flasks at roughly 5  106 cells per flask with 5
ng/mL CSF-1 added to the medium, and incubated for 24 hours at 37°C in
5% CO2 in a humidified incubator to allow stromal cells to adhere, after
which the nonadherent cells were collected, suspended in complete medium
containing 75 ng/mL CSF-1 and plated at a density of at least 5  105 cells
per well in 12-well plates. After 2 days, the medium was changed, this time
containing 75 ng/mL CSF-1 and 30 ng/mL RANKL. Subsequently, medium
was replaced every 2 to 3 days. In some wells, antichemokine antibodies
(anti–mouse -CCL9, -CCL3, or -CCL5; all affinity-purified immunoglobu-
lin G [IgG] fraction rabbit antibodies; Peprotech) were added to the medium
at the time of RANKL addition at concentrations of 0.5 and 1.5 g/mL.
Following 1 week of differentiation, cells were fixed in 4% paraformalde-
hyde, processed for TRAP histochemical staining as described, and
TRAP-positive cells with 3 or more nuclei were counted in at least 6 wells
in each of at least 3 replicate experiments.
In situ hybridization
Long bones were harvested, fixed in 4% paraformaldehyde, demineralized
with EDTA, paraffin-embedded, and subjected to in situ hybridization as
previously described.26 Briefly, digoxigenin-UTP (Roche Diagnostics) was
incorporated into a riboprobe for rat CCL9 using the T7 Ampliscribe kit27
(Epicentre, Madison, WI) with the rat CCL9–containing plasmid pCDNA3-
rCCL9 as a template.12 Following blocking and hybridization at 42°C,
probe was detected with alkaline phosphatase–conjugated antidigoxigenin,
and signal was developed with NBT/BCIP substrate.
Immunohistochemistry
Bones were fixed, demineralized, and paraffin-embedded as described, and
7-m-thick sections were cut. Peroxidase activity was blocked with 3%
H2O2 and the sections were then blocked with 5% BSA and 5% normal goat
serum for 2 hours. After blocking, they were incubated with rabbit
polyclonal anti-CCL9 IgG fraction (Peprotech) overnight at 4°C. Following
4 washes in PBS with 5% normal goat serum, biotinylated secondary goat
anti-rabbit antibody (Dako, Carpinteria, CA) was added and incubated for 1
hour at room temperature. After additional rinsing, ABC signal amplifica-
tion reagent (Dako) was added, followed by avidin horseradish peroxidase
(HRP) complex (Dako), and finally by DAB substrate. The reaction was
stopped with H2O rinses and slides were treated with AquaPerm (Thermo
Shandon, Pittsburgh, PA) reagent before coverslipping.
Microscopic imaging
Images were obtained using a Zeiss Axioskop 2 Plus with a brightfield
condenser and equipped with a Zeiss Axiocam HRc color digital camera
and Zeiss Axiovision software (4.0; Zeiss, Oberkochen, Germany)
Statistical analysis
Routine statistical comparisons were performed using Microsoft Excel.
Following F tests to determine equality of sample variances, 2-tailed t tests
were done to compare sample means obtained from replicates of microarray
data, real-time PCR, and osteoclast counts. All data are reported as
mean plus or minus 1 standard deviation.
Results
CSF-1–induced osteoclastogenesis
Preliminary experiments were done to determine the time course
over which CSF-1 injections would induce osteoclastogenesis in
3-week-old tl/tl rats. No osteoclasts were seen in multiple sections
of tibia from untreated tl/tl rats at any time point, and treatment for
2, 4, 6, and 24 hours produced no TRAP-positive cells (not shown).
Later time points were analyzed, and the results are shown in
Figure 1. TRAP-positive osteoclasts first appeared after 2 days of
CSF-1 treatments, with about 1 osteoclast per slide in areas A (near
the chondroosseous junction) and B (further down in the metaphy-
sis). The counts reached a maximum on day 4, averaging approxi-
mately 10 and 18 cells per slide in the 2 areas. By day 6, counts
declined slightly to about 7 and 12 cells per slide in areas A and B,
respectively. This decline coincided with the reduction in bone area
that resulted from the rapid, ongoing bone resorption, leaving less
bone surface for osteoclast attachment. Using these results as a
guide, we established a time course of 2, 4, and 6 days to measure
gene expression changes by microarray from the first appearance of
differentiated osteoclasts through and just past its peak.
Osteoclast gene expression
We ruled out any naturally occurring changes in osteoclast-
associated genes by following untreated tl/tl and / rats over the
same time course. Microarray analysis showed no significant
changes in the mRNA levels for the osteoclast markers TRAP or
Figure 1. TRAP-positive osteoclasts in tl rats in response to CSF-1 injections.
(A) TRAP staining of proximal tibial metaphysis reveals few osteoclasts by day 2 (red,
arrows), and well-established populations at days 4 and 6 (images were obtained
with a Zeiss Axioskop 2 Plus microscope with a 20 /0.5 NA brightfield objective).
None were seen at day 0 (not shown). (B) Cell counts were performed in a window of
defined size in 2 areas, area A near the chondro-osseous junction, and area B, in the
lower metaphysis, in replicate slides of multiple animals (n  24-36; bars show
mean 1 SD).
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cathepsin K in either tl/tl mutants or / littermates, nor did
CSF-1 injections induce significant changes in osteoclast-
associated genes in / littermates. The average value for
wild-type rats, treated or untreated, was 7490 RU for TRAP and
11 485 for cathepsin K. Table 1 summarizes array results for
osteoclast-associated genes in the CSF-1–treated tl/tl mutants over
the time course. TRAP mRNA levels increased significantly in a
manner that paralleled the osteoclast counts, rising 5-fold on day 2,
doubling again on day 4, and slightly decreasing on day 6 (P values
compared with day 0: day 2, P  .01; day 4, P  .001; and day 6,
P  .001). The pattern for cathepsin K mRNA in treated tl/tl
mutants was nearly identical to TRAP, as was its statistical
significance. The CSF-1 receptor (c-Fms) had a different pattern,
increasing more than 5-fold over the day 0 to a peak on day 2, then
slightly decreasing on days 4 and 6 (P  .001 for days 2, 4, and 6
compared with day 0). RANK, the receptor for RANKL, which is
expressed in committed preosteoclasts and mature osteoclasts and
is induced by CSF-1 in vitro, was not present on the microarrays.
Because of its importance in osteoclast differentiation, we analyzed
RANK mRNA by real-time PCR. RANK expression was strongly
induced by CSF-1 and paralleled CSF-1 receptor mRNA, increas-
ing sharply on day 2, then subsiding gradually on days 4 and 6.
RANKL and its “decoy” receptor OPG, which, like CSF-1, are
supplied by osteoblasts in bone, showed modest changes. The
decrease in RANKL seen in Table 1 was significant only on day 6
(P  .05), whereas the slight increase in OPG was not statistically
significant (P 	 .05).
In summary, osteoclast-specific gene expression in total bone
RNA from treated mutants rose and fell with the same temporal
pattern as the osteoclast counts in bone tissue, and TRAP and
cathepsin K expression levels were of the same order as for
wild-type bone. Receptors required for osteoclastogenesis (c-Fms
and RANK) peaked early, on day 2, whereas markers of mature,
active osteoclasts (TRAP and cathepsin K) peaked later, simulta-
neously with osteoclast populations, roughly 4 days after commenc-
ing treatments with CSF-1. There was evidence that the rapid wave
of osteoclast induction and bone resorption did not feed back
quickly to affect the levels of either OPG or RANKL mRNA
expressed in bone tissue.
CCL9 and CCR1 expression
Among all genes induced in long-bone RNA from CSF-1-treated
tl/tl rats, 1 sequence, highly similar to the mouse CC chemokine
CCL9, stood out as being particularly strongly responsive. We
therefore cloned the complete cDNA and characterized it in greater
detail (GenBank accession no. AY863011), confirming it as the rat
ortholog of mouse CCL9, and demonstrating its potent chemotactic
effects in bone marrow mononuclear cell cultures.12 Figure 2 shows
that the expression profile for CCL9 mRNA as determined by
microarray (2A) was in good agreement with real-time PCR results
(2B). All 3 postinjection time points had highly elevated CCL9
mRNA compared with uninjected tl/tl mutants. Microarray results
were 78-fold higher on day 2 than day 0 (2260 vs 94 RU), 19-fold
higher on day 4, and 9-fold higher on day 6. All these differences
from the baseline value were statistically significant (P  .01 for
all postinjection time points). The real-time PCR results confirm a
large increase by day 2, up 32-fold (49 vs 1.5 RU), 21-fold on day
4, and 5-fold on day 6. We also tested samples 1 day after injection,
and the results showed that CCL9 had already risen to 2280 RU,
but also confirmed that the 2-day time point is the genuine peak of
CCL9 mRNA. In comparison, CCL9 mRNA did not change
significantly in untreated or CSF-1–treated / littermates over
the time course, averaging 2003 RU. The receptor for CCL9 is
CCR1, or MIP-1 receptor. It changed in a similar pattern to its
ligand (Table 1 and Figure 2C). The level rose to roughly 5 times
the baseline value on day 2, then declined gradually over the next 4
days. The differences between day 0 and subsequent days were
significant (P  .005 on days 2 and 6, and P  .02 on day 4).
CCR1 mRNA did not change significantly in untreated or treated
/ littermates over the time course.
Sequence identification and expression of other chemokines
and receptors
Because the interactions among chemokines and their receptors are
complex, we closely examined expression of all the chemokines
and receptors represented on the rat microarrays. The rat chemo-
kine and receptor repertoire is not as thoroughly established as that
for human or mouse. We therefore did BLAST searches of potential
chemokine and receptor sequences represented on the gene arrays
against the rat genome to obtain full-length cDNA sequences,
where available. These in turn we could use to BLAST mouse and
human sequences to identify homologous genes using the GenBank
UniGene resource. We also did the reverse, querying the chip
sequences with known chemokine and receptor sequences. This
allowed us to assign identities to the sequences present on the rat
arrays. The identities given in Table 1 are either established in the
rat or have the highest homology to known mouse chemokines/
receptors (	 70% identical and 	 80% similar amino acids). If no
sequence on the chips met this level of homology, we report it as
“not present” on the chip. Likewise, if there was no rat sequence in
GenBank with sufficient homology to known chemokines or
receptors, we report it as such. The expression levels for all
chemokines and receptors on the microarrays over the time course
are shown in Table 1.
In addition to the dramatic changes in CCL9 and CCR1
described, several other genes were of interest. For example,
CXCL4 (platelet factor 4 [PF-4]) was reported to inhibit parathy-
roid hormone (PTH)–stimulated bone resorption,28 to promote
monocyte survival and differentiation into macrophages,29 and to
inhibit angiogenesis.30 Its expression level doubled over the time
course from approximately 5000 to just over 10 000 RU. The slight
increase on day 2 was not significant (P 	 .1), but it was significant
on day 4 (P  .05), and highly significant on day 6 (P  .001).
Whether this increase is related to its potential regulatory effect on
monocytes or to other activities (eg, regulating vascularization of
the nascent marrow space) remains to be investigated. A recent
report31 suggested that CXCR3 exists in 2 isoforms, A and B, and
that CXCR3-B may be the receptor that mediates the actions of
CXCL4.31 We did not detect significant changes in this receptor
over the time course.
Yu et al15 demonstrated a potential role for CXCL12 (SDF-1)
and its receptor, CXCR4, in the migration of preosteoclasts to sites
of bone resorption, based on their expression in endothelial and
stromal cells and chemotactic effect on the murine preosteoclast-
like cell line, RAW 264.7. In our microarray time course, the
mRNA level for neither CXCL12 nor CXCR4 varied significantly
(P 	 .05), except for a slight increase in the receptor seen on day 2
(P  .05). Thus, the levels in vivo were fairly constant, despite the
extraordinary increases taking place in osteoclasts and
resorptive activity.
The modest increase in CCL6 on day 2 was significant
(P  .05), but not for the later time points (P 	 .1). Similarly, for
CCL2 (monocyte chemoattractant protein-1 [MCP-1]), there was a
small increase on day 2 that was significant (P  .05), but not on
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Table 1. Relative gene expression for osteoclast-associated genes, chemokines, and chemokine receptors
Gene name Alternative names
GenBank
accession no.
RAE230 array
probe set
Expression, microarray relative units 1 SD
Day 0 Day 2 Day 4 Day 6
Control/osteoclast genes
GAPDH — NM_017008 1367557_s_at 9750 
 2181 10 737 
 1 446 11 282 
 2 216 11 111 
 1 496
Acid phosphatase 5 TRAP NM_019144 1367942_at 1212 
 378 6 677 
 2 294 12 001 
 739 10 454 
 265
Cathepsin K — NM_031560 1369947_at 1789 
 487 8 906 
 2 818 14 564 
 994 12 657 
 1 475
RANKL TRANCE, TNF superfamily member 11 NM_057149 1369282_at 679 
 209 981 
 263 484 
 117 385 
 59
OPG Osteoprotegerin, TNF receptor
superfamily, member 11b
NM_012870 1369407_at 325 
 54 331 
 15 452 
 75 422 
 63
CSF-1 receptor c-Fms BI285793 1388784_at 770 
 99 4 310 
 1 337 3 127 
 644 2 462 
 327
Chemokines/Receptors
CC chemokines
CCL1 (NRS) — — — — — — —
CCL2 MCP-1 NM_031530 1367973_at 189 
 80 456 
 184 534 
 361 257 
 77
CCL3 MIP-1 U22414 1369815_at 420 
 94 566 
 46 425 
 70 429 
 63
CCL4 MIP-1 NM_053858 1370832_at 385 
 103 386 
 34 323 
 42 321 
 36
CCL5 RANTES NM_031116 1369983_at 565 
 83 450 
 74 532 
 112 545 
 120
CCL6 MRP-1 BE095824 1389123_at 1131 
 378 2 244 
 720 919 
 247 1 358 
 367
CCL7 MCP-3 BF419899 1379935_at 117 
 20 113 
 10 128 
 24 93 
 26
CCL8 (NRS) MCP-2 — — — — — —
CCL9 MIP-1 AI169984 1392172_at 100 
 94 7 832 
 2 260 1 898 
 783 858 
 385
CCL11 Eotaxin NM_019205 1387319_at 257 
 20 243 
 26 218 
 29 213 
 18
CCL12 (NP) MCP-5 XM_213425 — — — — —
CCL13 (NRS) MCP-4 — — — — — —
CCL15 (NRS) HCC-2 — — — — — —
CCL17 TARC NM_057151 1370118_at 187 
 11 175 
 8 166 
 12 185 
 26
CCL19 ELC, MIP-3 AA996885 1391925_at 622 
 195 478 
 144 517 
 108 517 
 196
CCL20 MIP-3 AF053312 1369814_at 229 
 23 196 
 22 223 
 13 274 
 50
CCL21 6CKINE BI282920 1378015_at 320 
 26 417 
 56 374 
 104 431 
 49
CCL22 MDC AF432871 1370619_at 207 
 12 208 
 23 178 
 34 169 
 44
CCL25 (NP) TECK — — — — — —
CCL26 Eotaxin-3 BI294084 1385309_at 662 
 181 742 
 67 804 
 145 636 
 64
CCL27 CTACK XM_342823 1376850_a_at 463 
 27 390 
 40 356 
 66 386 
 84
CXC chemokines
CXCL1 GRO NM_030845 1387316_at 96 
 12 115 
 6 123 
 21 108 
 34
CXCL2 GRO, MIP-2 NM_053647 1368760_at 498 
 124 406 
 72 408 
 47 362 
 172
CXCL4 Platelet factor 4, PF-4 AI169104 1371 250_at 5004 
 632 5 172 
 297 7 687 
 566 10 210 
 538
CXCL5 CXC chemokine LIX, ENA-78 NM_022214 1387648_at 233 
 100 148 
 148 156 
 41 119 
 72
CXCL8 (NRS) IL-8 — — — — — —
CXCL9 MIG AI044222 1382454_at 155 
 19 137 
 12 142 
 30 137 
 15
CXCL10 CRG-2, IP-10 U22520 1387969_at 173 
 20 152 
 29 171 
 18 190 
 29
CXCL11 I-TAC BF281987 1379365_at 90 
 21 90 
 15 86 
 12 94 
 19
CXCL12 SDF-1 AI171777 1369633_at 4661 
 1007 5 563 
 1 201 5 371 
 917 5 893 
 1 062
CXCL13 BCA-1 AA892854 1398390_at 353 
 54 351 
 54 359 
 66 421 
 129
CXCL14 BRAK, BOLOKINE AI412979 1396129_at 505 
 69 838 
 440 493 
 106 675 
 101
XCL1 Lymphotactin NM_134361 1387831_at 53 
 27 36 
 44 63 
 62 64 
 30
CX3CL1 Fraktalkine NM_134455 1368200_at 228 
 112 257 
 29 215 
 69 239 
 53
Receptors
CCR1 MIP1-R, RANTES-R NM_020542 1370083_at 237 
 74 1 122 
 310 829 
 306 523 
 117
CCR2 MCP-1 R NM_021866 1387742_at 135 
 45 155 
 27 125 
 9 115 
 38
CCR3 Eotaxin R NM_053958 1369808_at 297 
 97 244 
 67 224 
 21 223 
 63
CCR4 — NM_133532 1369555_at 189 
 49 187 
 39 156 
 19 185 
 68
CCR5 — NM_053960 1369290_at 115 
 18 126 
 23 107 
 17 90 
 14
CCR6 GRO/MGSA-R, STRL22 AI045155 1393929_at 1148 
 126 1 075 
 142 1 180 
 122 1 031 
 168
CCR7 (NP) — — — — — — —
CCR8 (NP) — — — — — — —
CCR9 (NP) — — — — — — —
CCR10 (NP) — — — — — — —
CXCR1 IL-8 RA NM_019310 1369875_at 288 
 33 259 
 52 272 
 30 270 
 29
CXCR2 IL-8 RB NM_017183 1369697_at 241 
 37 223 
 20 260 
 31 242 
 50
CXCR3 MIG-R, IP-10 NM_053415 1368192_at 312 
 46 312 
 56 356 
 69 318 
 56
CXCR4 LCR1, SDF1-R, U54791 1389244_x_at 4083 
 521 4 902 
 110 3 203 
 614 4 156 
 619
Fusin
CXCR5 Burkitt lymphoma receptor 1 NM_053303 1369911_at 669 
 104 513 
 65 524 
 106 507 
 63
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subsequent days. CCL3 (MIP-1) did not change significantly, and
its expression was at low levels throughout the time course. All
other chemokines and receptors showed little or no change in
RNA levels.
In situ hybridization
Because of the complexity of bone tissue, with osteoblasts,
osteoclasts, endothelium, and stromal and hematopoietic cells all in
close proximity, we sought to determine whether the cellular source
of CCL9 mRNA in vivo could be unambiguously attributed to
osteoclasts and/or their precursors. In situ hybridization using a
CCL9 riboprobe was therefore performed on the contralateral
tibiae of the animals used for RNA isolation, and the results are
shown in Figure 3 (negative controls using sense probe gave no
reactivity; not shown). CCL9 mRNA was abundant in immature
osteoclasts (Figure 3B-C) at day 2 and in mature osteoclasts at days
4 and 6 (Figure 3D-G). In immature cells, prior to fusion and
Figure 2. CCL-9 and CCR1 mRNA expression in long bones determined by
microarray and real-time PCR. tl rats were treated for the days indicated and total
bone RNA was analyzed. CCL9 and CCR1 mRNA were highest after 2 days of
treatment, after which the levels subsided. Means 1 SD are shown. Compared with
untreated animals (day 0), all time points were significantly elevated. (A-B) *Differ-
ence from day 0, P  .01. (C) *Difference from day 0, P  .005; **P  .02.
Figure 3. In situ hybridization for CCL-9 mRNA during CSF-1 time course,
proximal tibia of tl rat. No CCL-9-expressing cells were visible at day 0 (A).
CCL-9-positive cells are indicated in panels B-D with arrows. Many small cells were
detected at day 2 (B,E), and larger osteoclasts were seen at days 4 (C,F) and 6 (D,G).
Higher magnification revealed cytological features of the CCL-9-expressing cells.
Arrows in panels F and G indicate some individual nuclei. The cells seen at day 2
were typically smaller, mononuclear, and less differentiated, while at days 4 and 6,
osteoclasts generally contained multiple nuclei and were better differentiated. The
CCL-9 mRNA is diffusely distributed throughout the cytoplasm in the differentiating
mononuclear pre-osteoclasts in panel E, but appears highly concentrated in the
ruffled border area in days 4 (F) and 6 (G). *Bone trabeculae. Original magnifications:
 100 (A-D); 630 (E-G). No counterstain was used.
Table 1. Relative gene expression for osteoclast-associated genes, chemokines, and chemokine receptors (continued)
Gene name Alternative names
GenBank
accession no.
RAE230 array
probe set
Expression, microarray relative units 1 SD
Day 0 Day 2 Day 4 Day 6
CXCR6 (NRS) — — — — — — —
CX3CR1 V28 NM_133534 1369527_at 520 
 96 411 
 43 468 
 96 508 
 94
XCR1 (NP) GPR-5 — — — — — —
NRS indicates no sequence for rat in GenBank with sufficient homology to assign identity; NP, no sequence present on the RAE 230 chipset used. mRNA levels were
determined by DNA microarray analysis of tibial RNA isolated from toothless (tl/tl) rats on day 0 (3 weeks old), or following 2, 4, and 6 days of CSF-1 injections to induce
osteoclast differentiation. Values shown are the mean 
 1 SD of 4 individual animals. GAPDH served as an internal standard. Osteoclast-specific genes include TRAP,
cathepsin K, and the CSF-1 receptor (c-Fms). We also show results for the osteoblast-derived osteoclast-inducing factor RANKL and its decoy receptor OPG, which underwent
little or no change in this experimental system. TRAP and cathepsin K mRNA levels follow the same time course as osteoclast counts in bone sections. CCL9 and its receptor
CCR1 showed by far the greatest responses of all chemokines and receptors and peaked a full 2 days before osteoclast counts, as did CSF-1 receptor levels. Chemokine and
receptor identities were assigned based on highest homology to mouse, determined as described in “Results.”
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attainment of the mature differentiated state, there was strong
signal for CCL9 mRNA dispersed throughout the cytoplasm. In
mature osteoclasts, however, the message often had a very unusual
distribution, appearing highly concentrated in the area of the ruffled
border, adjacent to the bone surface, and very little was detected in
the remainder of the cell. This was a consistent finding and is very
different from the distribution of TRAP mRNA in similar experi-
ments (not shown) and from the CCL9 protein (Figure 4), although
its significance remains to be explored.
Immunohistochemistry
Immunohistochemistry was performed on sections from the same
tissues examined by in situ hybridization to determine whether the
CCL9 mRNA is translated into protein and to establish its
distribution in the bone tissues (Figure 4). CCL9 was not detected
in tl/tl day-0 samples (not shown), but was seen in day-2, -4, and -6
bone sections. Close inspection confirmed that CCL9-positive cells
were typically small on day 2 (Figure 4A), and were relatively
strongly labeled. Lower intensity of anti-CCL9 labeling was seen at
the later time points, and tended to occur in large, multinucleated
osteoclasts that often contained vacuoles (Figure 4B), indicative of
active ingestion of bone matrix. This confirms that both the mRNA
and its translated product are expressed by osteoclasts in vivo
beginning early in the differentiation process.
Osteoclast differentiation in bone marrow cell cultures
CSF-1 and RANKL were added to normal rat bone marrow cell
cultures to induce osteoclast differentiation in the presence or
absence of the same anti-CCL9 polyclonal antibody used for
immunostaining. Multinucleated TRAP-positive cells were counted
(Figure 5). In control wells, without anti-CCL9 added, there were
on average 379 
 147 (mean 
 SD; n  19) osteoclasts per well.
With 0.5 g antibody per well added, that decreased to 106 
 62
(n  9), and in the presence of 1.5 g antibody, the average was
83 
 77 (n  9). The decreases were highly significant for both
concentrations of anti-CCL9 antibody (P  .01). In control experi-
ments, the addition of anti-CCL3 or anti-CCL5 (both of these
chemokines bind CCR1, the same receptor as CCL9) had no
significant effect on differentiation at either concentration (data
not shown).
Anti-CCL9 inhibition of osteoclastogenesis in vivo
Three tl/tl rats were treated with CSF-1, but were also given
anti-CCL9 antibody injections prior to and during their treatment
course to determine whether it would interfere with CSF-1–
induced osteoclastogenesis. Tissues were collected at 4 days, the
time of the osteoclast peak counts, and TRAP-positive osteoclasts
were counted (Figure 6). The anti-CCL9 treatment reduced the
osteoclast counts in both area A and area B in comparison to tl/tl
mutants treated with CSF-1 alone. The differences were highly
significant: in area A, 9.3 
 4.1 versus 16.8 
 2.8 (P  .001); for
area B, 10.8 
 7.4 versus 21.5 
 4.0 (P  .001) (mean
 SD).
Discussion
Together, the gene expression profiles for TRAP, cathepsin K,
CCL9, and CCR1, and the osteoclast counts in bone over the time
course suggest that CCL9 acts in vivo early in osteoclast differen-
tiation. Given CCL9’s chemotactic effects on mononuclear precur-
sors in mouse13,14 and rat,12 it presumably is guiding them to sites
where they will fuse and fully differentiate. The results also suggest
that the average time required for CSF-1–induced osteoclast
differentiation from precursors in vivo was roughly 4 days.
The fact that anti-CCL9 antibody suppressed the appearance of
TRAP-positive osteoclasts when injected in vivo provides strong
Figure 4. Immunohistochemistry for
CCL-9 in the proximal tibia of tl rats.
Immunohistochemistry after 2 (A), 4 (B), or
6 (C) days of CSF-1 injections is shown.
Orange-brown color indicates CCL-9 pro-
tein. At day 2, the staining was most evident
in small, newly formed osteoclasts, while at
days 4 and 6, large, mature osteoclasts
were present with much weaker, more dif-
fuse labeling. *Bone trabeculae; v indicates
a prominent vacuole in the large osteoclast
in panel B. Scale bar in panel C equals 21
m. Shown are 10-m paraffin sections
without counterstain. Objective magnifica-
tion: 63 /1.25 NA.
Figure 5. Inhibition of CCL9 blocks osteoclast differentiation in vitro. Rat BMCs
were induced to differentiate into osteoclasts using CSF-1 and RANKL. Anti-CCL9
antibody blocked the formation of TRAP-positive, multinucleated cells. Means  1
SD are shown. For both antibody concentrations tested, the decrease was highly
significant. *P  .001.
Figure 6. Injections of anti-CCL9 suppress osteoclast differentiation in vivo. tl/tl
rats were injected either with CSF-1 alone or with anti-CCL9 antibody and CSF-1, and
TRAP osteoclasts were counted on multiple sections of the proximal femur from 3
animals for each condition after 4 days of injections. Anti-CCL9 significantly reduced
the osteoclastogenic response to CSF-1 injections. Means 1 SD are shown. In both
areas, differences were highly significant (*P  .001).
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evidence for its importance in early events in osteoclastogenesis.
Because the antibody was in limited supply, we have not deter-
mined whether the suppression of osteoclast differentiation would
have been greater if higher doses of antibody were used, or was
partially compensated by other chemokines. CCL-9 was recently
shown to be highly expressed during mouse osteoclast differentia-
tion in vitro, and inhibiting it with anti-CCL9 antibody interfered
with osteoclast differentiation in primary mouse cell cultures.13,14
The extremely strong induction of CCL9, and not of other
chemokines, in long bones of CSF-1–treated tl/tl rats establishes
several things. First, it demonstrates that the increases seen in
earlier studies of cultured cells also take place within the context of
living bone. Second, it establishes that CCL9, among all the
chemokines we studied, plays the decisive role in promoting
osteoclastogenesis in response to CSF-1 and RANKL. Third, it
shows that CCL9 is playing a similar role in the rat as in the mouse,
which is important to confirm since the chemokines are such a large
and diverse family, with multiple ligand/receptor interactions, and
substantial variation from species to species.
The lack of marked changes in other chemokines and their
receptors is consistent with the work of Lean et al,14 in which a
survey of all known chemokine and receptor mRNAs was carried
out during the RANKL-induced differentiation of normal mouse
bone marrow mononuclear cells. They found CCL9 and its
receptor, CCR1, to be those most highly expressed after 5 days of
treatment with CSF-1 and RANKL, but this did not occur if only
CSF-1 was used. The next most highly expressed chemokine
mRNAs in their analysis were CCL12 and CCL25. Unfortunately,
neither of those ligands was represented on the rat arrays, so more
detailed investigations in rat bones have not been done by us at
present. Given the dependence on CSF-1 and RANKL that those
authors found for CCL9 and CCR1 expression, we infer that the
increases in our test system result not from the actions of CSF-1
alone, but rather from the combined effects of the injected CSF-1
and normal RANKL expressed in the tl/tl rat bone.
Another ligand for CCR1, CCL3 (MIP-1), was shown several
years ago to promote osteoclast differentiation in vitro.32 A report
showed that CCL3 promoted tumor invasiveness in mouse models
and that its inhibition by anti–MIP-1 antibody reduced myeloma-
induced osteolysis.18 CCL3 and the other ligands that bind
CCR1—CCL5 and 7—were examined in RAW264.7 cells, a
mouse cell line that becomes osteoclast-like in response to
RANKL, and in primary mouse marrow-derived cells.17 These
authors found that CCL3, CCL5, and CCL7 all exerted chemotactic
effects. Because those chemokines are all normally expressed by
osteoblastic or other cell types in the bone environment, the authors
correctly point out that their misexpression could lead to increased
fusion and differentiation of osteoclasts at inappropriate sites and
could contribute to pathologic bone loss in vivo, as CCL3 has been
shown to do. During our time course, however, expression of
CCL3, CCL5, and CCL7 did not change. Additionally, neither
anti-CCL3 nor anti-CCL5 inhibited osteoclast differentiation in
bone marrow cell culture experiments, whereas anti-CCL9 had a
highly significant inhibitory effect (Figure 5). We conclude that
although the other CCR1 ligands are potential mediators of
pathological bone resorption, at least in rodent models, CCL9
normally plays the decisive role.
One question that remains open is whether, if the CCL9 gene
were knocked out, other chemokines would be able to compensate.
The CCR1 receptor has been knocked out, but those authors did not
note a skeletal phenotype,33-35 implying that compensation has
occurred. A knockout mouse model for CCL9 deficiency would
shed light on this question and provide further information on
whether chemokine pathways overlap to regulate bone mass.
The lack of change in several other chemokines and receptors
also deserves consideration. CXCL12 (SDF-1) has been shown to
exert significant chemotactic activity on RAW cells, which express
high levels of its putative receptor, CXCR4.15 Further work in
RAW cells showed an induction of the tissue remodeling enzyme
MMP9 by CXCL12,16 suggesting a role for CXCL12 in promoting
the extravasation of osteoclast precursors and guiding their
migration to appropriate bone resorption sites. Our findings are
not inconsistent with those results, in that the near-constant
levels of CXCL12 and CXCR4 in our time-course may be
sufficient for these activities without necessitating additional
transcription. It is clear, however, that the levels we saw in vivo
were not responsive to the sudden appearance of normal CSF-1
levels and were independent of the resulting rapid, large-scale
osteoclast differentiation.
The validity of rodent models to study the skeletal biology of
higher vertebrates is fully supported by the high conservation of
many signaling pathways, growth factors, and receptors between
them and humans. The chemokines, however, are not so closely
conserved across species. In our own investigations, we found
many examples of extremely high conservation between rat and
human, but also abundant cases of comparatively large divergence
or even missing family members. Thus, precisely how our results in
the rat and others’ findings in the mouse correspond to human
skeletal biology remains to be firmly established, and has not been
thoroughly addressed to date. This is a significant challenge, given
the complex interactions among chemokines and their receptors. In
human osteoclast cultures, a recent report showed that the CXCL10
and CXCL12 were up-regulated specifically when cells were
cultured on calcium phosphate–coated surfaces, but not when
grown on plastic.36,37 In our experimental system, however, we did
not observe changes in those ligands during osteoclast differentia-
tion in vivo, although CXCL12 was indeed present at fairly high
levels throughout the time course. Neither did we observe signifi-
cant changes in several other chemokines and receptors those
workers found in human osteoclast cultures. Another example is
CXCL8 (IL-8), which was shown to have chemotactic and
activating effects on human peripheral blood mononuclear cell–
derived osteoclasts, and also to stimulate RANKL synthesis by
MC3T3 cells.38 To date, however, no highly homologous gene to
CXCL8 has been identified in either the rat or mouse genome,
leaving the question open as to how the equivalent response would
be triggered in rodent osteoclasts.
CCL9 clearly plays a key role in nonpathological osteoclast
induction in vivo in the rat, and almost certainly in the mouse, but
which chemokine plays the analogous role in human osteoclast
recruitment and differentiation remains an important unanswered
question. The nearest matches at the amino acid sequence level are
CCL15, or A15 (GenBank no. NP_116740.2), and CCL23, or A23
(GenBank accession no. NP_005055.2), both of which are CCR1
ligands and can also bind to CCR3. Both are only moderately
similar to rat CCL9. CCL15 has 42% identity and 59% total
similarity, and CCL23 has 38% identity and 58% similarity. With
human osteoclastoma cells, CCL15 was found to have chemoattrac-
tant activity.39 The degree of similarity of these human chemokines
to rat CCL9 is not especially noteworthy. For example, rat CCL3
has a much closer human homolog, also designated CCL3 (Gen-
Bank accession no. AAH27888). The rat and human CCL3 proteins
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share 74% amino acid identities and 84% total similarity, which is
fairly typical. It would therefore appear that evolution has selected
a different chemokine to modulate osteoclast ontogeny in humans
versus the 2 rodent species. Future work focused on the role of
CCL15 and/or other, less homologous candidates should establish
the identity of the key human osteoclastogenic chemokine(s) in
nonpathological osteoclast induction.
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